ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)

HKG:1541 Revenue

ImmuneOnco Biopharmaceuticals (Shanghai) had revenue of 37.25M CNY in the half year ending June 30, 2026, with 5,080.39% growth. This brings the company's total for the last twelve months to 147.53M, up 25.61% year-over-year. In the year 2025, ImmuneOnco Biopharmaceuticals (Shanghai) had annual revenue of 154.29M with 108.09% growth. That makes ImmuneOnco Biopharmaceuticals (Shanghai) the 33,323rd largest company in the world by revenue and 2,000th in Hong Kong.

• Revenue (ttm): 147.53M CNY
• Revenue Growth: +25.61%
• P/S Ratio: 7.29
• Revenue / Employee: 748.87K CNY
• Employees: 197
• Market Cap: 1.22B HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue by Geography

Chart

• United States of America 154.20M 99.9%
• PRC 97.00K 0.1%

Fiscal year ended Dec 31, 2025 See the full HKG:1541 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	154.29M	80.15M	108.09%
Dec 31, 2024	74.15M	66.45M	863.60%
Dec 31, 2023	7.70M	2.01M	35.24%
Dec 31, 2022	5.69M	-8.12M	-58.79%
Dec 31, 2021	13.81M	-	-

Data Source: S&P Global Market Intelligence Last updated: Sep 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Nov 1, 2026

Data Sources Report a data error